Email this article Experience in using immunal in the complex treatment of patients with torpid peptic ulcer
- Authors: Vakhrushev Y.M.1, Balagatdinov A.R.1, Vakhrushev Y.M1, Balagatdinov AR1
-
Affiliations:
- Ижевская государственная медицинская академия
- Issue: Vol 82, No 2 (2010)
- Pages: 13-17
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30534
- ID: 30534
Cite item
Full Text
Abstract
Aim. to provide a rationale for the use of immunal in intractable gastroduodenal peptic ulcers (PU), by studying Helicobacter pylori genotypes and immunological parameters.
Subjects and methods. Sixty-eight patients (37 men and 31 women) with torpid PU were examined. A study group comprised 35 patients who took immunal as a component of complex eradication therapy; a control group included 33 patients who received complex eradication therapy only. In addition to clinical and endoscopic data, the values of H. pylori genotypes were used to evaluate therapeutic efficiency.
Results. The inclusion of immunal into the complex therapy in patients with torpid PU exerts a significant clinical effect in relieving the pain syndrome and dyspeptic symptoms and in accelerating ulcer cicatrization. The disappearance of virulent H. pylori strains was noted during treatment. Recovery of phagocytic, cellular, and humoral immunities is an important result of therapy.
Conclusion. The use of immunal as a component of complex therapy for torpid PU is pathogenetically founded and clinically effective.
Subjects and methods. Sixty-eight patients (37 men and 31 women) with torpid PU were examined. A study group comprised 35 patients who took immunal as a component of complex eradication therapy; a control group included 33 patients who received complex eradication therapy only. In addition to clinical and endoscopic data, the values of H. pylori genotypes were used to evaluate therapeutic efficiency.
Results. The inclusion of immunal into the complex therapy in patients with torpid PU exerts a significant clinical effect in relieving the pain syndrome and dyspeptic symptoms and in accelerating ulcer cicatrization. The disappearance of virulent H. pylori strains was noted during treatment. Recovery of phagocytic, cellular, and humoral immunities is an important result of therapy.
Conclusion. The use of immunal as a component of complex therapy for torpid PU is pathogenetically founded and clinically effective.
About the authors
Yakov Maksimovich Vakhrushev
Ижевская государственная медицинская академияд-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней; Ижевская государственная медицинская академия
Anvar Raifovich Balagatdinov
Ижевская государственная медицинская академияаспирант каф. пропедевтики внутренних болезней; Ижевская государственная медицинская академия
Ya M Vakhrushev
A R Balagatdinov
References
- Аруин Л. И., Логинов А. С., Ильченко А. А. Язвенная болезнь и Helicobacter pylori. Новые аспекты патогенетической терапии. М.: Медицина; 1993.
- Пальцев А. И., Джуробаева М. К. Анализ состояния заболеваемости органов пищеварения в Новосибирской области. Сиб. журн. гастроэнтерол. и гепатол. 1999; 8: 72- 74.
- Аруин Л. И. Helicobacter pylori и хронизация гастродуоденальных язв. Клин. мед. 2000; 3: 60-64.
- Бардахчьян Э. А., Ломов С. Ю., Камнева Н. В., Харланова Н. Г. Проблема антибиотикорезистентности Helicobacter pylori и пути ее преодоления. Экспер. и клин. гастроэнтерол. 2002; 5: 21-23.
- Вахрушев Я. М. Внутренние болезни. Ижевск: Экспертиза; 2000.
- Арутюнян В. М., Григорян Э. Г. Эффективность применения иммуномодуляторов в комплексном лечении больных хроническим гастритом и язвенной болезнью. Клин. мед. 2003; 5: 33-55.
- Циммерман Я. С., Михалева Е. Н. Язвенная болезнь и иммунная система. Клин. мед. 2000; 7: 35-40.
- Циммерман Я. С., Михалева Е. Н. Состояние иммунной системы у больных язвенной болезнью двенадцатиперстной кишки и влияние на нее современной терапии и иммуномодулирующих средств. Клин. мед. 2003; 1: 40-44.
- Labinge A., de Reuse H. Determinants of Helicobacter pylori pathogenicity. Infect. Agents Dis. 1996; 5: 191-202.
- Xiang Z., Censini S., Bayeli P. F. et al. Analysis of expression of Cag and Vac A virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be devided into two major types and that Cag A is not necessary for expression of the vacuolating cytotoxin. Infect. and Immun. 1995; 63: 94-98.
- Маев И. В., Гаджиева М. Г., Овчинникова Н. И. Иммунные нарушения при эрозивно-язвенных поражениях слизистой оболочки гастродуоденальной зоны. Клин. мед. 2004; 12: 4-9.
Supplementary files
